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Abstract
During cerebral ischemia, elevation of TNF-a and glutamate to pathophysiological levels may induce dysregulation
of normal synaptic processes, leading ultimately to cell death. Previous studies have shown that patients subjected
to a mild transient ischemic attack within a critical time window prior to a more severe ischemic episode may
show attenuation in the clinical severity of the stroke and result in a more positive functional outcome. Studies
with organotypic hippocampal cultures and mixed primary hippocampal cultures have shown that prior incubation
with low concentrations of glutamate and TNF-a increase the resistance of neurones to a subsequent insult from
glutamate, AMPA and NMDA, while co-exposure of TNF-a and for example AMPA may have neuroprotective
effects compared to cultures exposed to excitotoxic agents alone. In addition our work has shown that although
glutamate and TNF-a pretreatment induces analogous levels of desensitisation of the intracellular calcium
dynamics of neurons under resting conditions and in response to acute glutamate stimulation, their downstream
signalling pathways involved in this response do not converge. Glutamate and TNF-a would appear to have
opposing effects on resting Ca
2+ levels which supports the proposal that they have distinct modes of
preconditioning.
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Introduction
Stroke and brain function
As neurons are incapable of storing glucose, they rely on
the cardiovascular system and astrocytes to deliver this
source of energy. Thus, the depletion of oxygen
(hypoxia) and glucose supply to the neuronal tissue dur-
ing a stroke, will result in inadequate aerobic metabo-
lism and failure of the cells to generate sufficient ATP
levels required to meet metabolic demand [1]. Mainte-
nance of Ca
2+ h o m e o s t a s i si sl o s td ue to insufficient
ATP to fuel extrusion pumps, while the resting mem-
brane potential is also disrupted due to dysfunction of
the Na
+/K
+ ATPase pumps, leading to ‘anoxic depolari-
sation’ [2]. The resulting ionic imbalance within the
neuronal and glial cells manifests in the development of
tissue acidosis [3], cytotoxic oedema and ultimately
necrosis [4]. The accumulation of cations in the cytosol
contribute to transient depolarisation at the nerve
t e r m i n a l s ,w h i c hi nt u r nt r i g g e r st h ea c t i v a t i o no fv o l -
tage-sensitive Na
2+ channels, amplifying the accumula-
tion of positive charge within the nerve terminal [5].
This increase in membrane potential will be detected by
the voltage sensors on the intracellular domain of vol-
tage-dependent Ca
2+ channels (VDCC) causing a large
influx of Ca
2+ into the terminal promoting vesicular
release of neurotransmitters and gliotransmitters such as
glutamate and/or TNF-a from neuronal/glial cells,
respectively [6], which at pathophysiological levels,
induce cellular toxicity [7,8]. Extracellular levels of glu-
tamate and TNF-a have been shown to remain elevated
in the infarct region for hours up to days after a stroke,
depending on the severity of the cerebral ischemic event
[9-11]. Due to the complex nature of cross-communica-
tion between neuronal and glial cells, the contribution
of glutamate and TNF-a to neurotoxicity during stroke
is intricately interlinked, with both cell types responsible
for the excessive elevation of these mediators to patho-
physiological levels, by paracrine and/or autocrine sig-
nalling [12]. * Correspondence: john.oconnor@ucd.ie
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TNF-a activity is mediated through activation of its sur-
face receptors, found on both neuronal [13,14] and glial
cell populations [15], along with endothelial cells of the
cerebral vasculature [16]. Two TNF-a receptors have
been identified, the low affinity TNFR1 (p55) and the
high affinity TNFR2 (p75) receptor [17]. Although the
extracellular domains to the TNFRs have a high degree
of homology, their intracellular domains do not [18],
which accounts for the complex signal transduction
pathways and corresponding proposed antagonistic
functions of these two receptor subtypes [17,19]. TNFRs
may exist as pre-aggregated membrane receptor com-
plexes, whereby TNF-a binds to its receptors as a
homo-trimeric protein [20], or may form hetero-recep-
tor complexes in response to ligand binding [21]. Upon
TNF-a binding, conformational change of the receptors
may lead to receptor endocytosis and exposure of its
intracellular binding sites for many adaptor proteins.
However, it is important to note that receptor shedding
from the membrane may also occur, which results in
the neutralisation of circulating TNF-a by acting as a
‘decoy receptor’ [22].
TNF-a-receptor-associated factor-2 (TRAF-2) was first
identified as a signal transducer molecule for the
TNFR2 TNF-a receptor [23]. TRAF-2 can bind directly
to the intracellular domain of TNFR2, and switch on
numerous signalling cascades which ultimately result in
the activation of the the NFBt r a n s c r i p t i o nf a c t o r .
TRAF-2 associates with receptor interacting protein
(RIP) which in turn activates IKb kinase (IKKb) to phos-
phorylate the inhibitory subunit of NFkB (IB), leading
to dissociation of this subunit, freeing the active NFB
transcription factor, which dimerises and translocates to
the nucleus to mediate gene transcription [24].
Further investigation has revealed a separate role for
TRAF-2 in TNFR1 downstream signalling. TNFR1 has
been dubbed the ‘death receptor’ due to the discovery of
an intracellular death domain sequence [25]. Upon
internalisation of the activated TNFR1 receptor, TNF
receptor-associated death domain (TRADD) adaptor
molecule associates with its death domain sequence and
signals the recruitment of TRAF-2 or RAIDD adaptor
protein to its receptor, to initiate downstream activation
of cysteine proteases, called caspases, involved in pro-
grammed apoptotic cell death. Fas-associated death
domain (FADD) can either bind directly to TNFR1
death domain sequence or to the TRAF-2-TRADD com-
plex and induce the auto-cleavage of pro-caspase 8 to its
active form [26], while association of TRADD with
RAIDD and receptor interacting protein (RIP) activates
caspase 2 [27]. See Figure 1 for details.
However, these signalling cascades are not mutually
exclusive to the individual receptors [28]. The activation
of TRAF-2 by TNFR1 stimulation has also the ability to
associate with RIP and initiate NFB and JNK signalling
leading to a neuroprotective response [29]. TNFRs have
also been shown to physically interact with insulin
receptor substrate-1 (IRS-1) and PI 3-kinase, which may
also contribute to the modulation of NFkB gene tran-
scription [30]. It seems that the rate and persistence of
NFB activation differ depending on receptor subtype
activated, which may account for the difference in their
overall response [19]. A study by Marchetti et al. (2004),
using TNFR1
-/
- and TNFR2
-/
- KO mice, found TNF-a
had a preconditioning effect on subsequent glutamate
insult in TNFR1
-/
- KO mice, whereas TNFR2
-/
- mice
were more susceptible to glutamate-induced excitotoxi-
city. The neurotoxic and neuroprotective effect of
TNFR1 and TNFR2, respectively, were further validated
using agonistic antibodies for these receptors [19]. This
study also found that NFBa c t i v i t yi nr e s p o n s et o
TNFR1 activation was rapid and transient, while TNFR2
activation resulted in a more slower but persistent
response. However, as most cell types express both
TNFR1 and TNFR2 their receptor activity are not
mutually exclusive. Individual receptor signalling may
also be confounded by the fact that these receptors may
aggregrate as heter-receptor complexes upon binding of
TNF-a [21]. Thus the overlap in their signalling cas-
cades adds to the complexity of the overall effect of
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Figure 1 Summary of TNFR signalling.T N F - a has two receptors
TNFR1 (R1) and TNFR2 (R2) which are co-expressed on both
neuronal and glial membranes. Activation of TNFR1 predominantly
results in the initiation of caspases involved in apoptosis. For this
reason, this receptor is known as the ‘death receptor’. However,
association of the death domain of this receptor with TRAF-2 can
lead to the activation of NFkB gene transcription and upregulation
of neuroprotective mediators such as the calcium chelator,
calbindin, and the superoxide scavenger, manganese superoxide
dismutase (MnSOD). This pathway is also shared with TNFR2
downstream signalling.
Watters and O’Connor Journal of Neuroinflammation 2011, 8:87
http://www.jneuroinflammation.com/content/8/1/87
Page 2 of 8TNF-a. It has been postulated that it is the ratio of
TNFR1:TNFR2 receptor expression that may govern the
overall TNF-a action. These receptors have been shown
to be constitutively expressed at different ratios on dif-
ferent cell types, and have been shown to be non-uni-
formly up-regulated in response to a variety of ligands
[15,31].
Contribution of TNF-a to cerebral ischemia
TNF-a is a well known cytokine involved in the inflam-
matory response elicited in the region of cerebral ische-
mia. Indeed, levels of TNF-a may remain elevated in
the affected brain tissue for at least 24 h after an
ischemic insult [9,10]. However the function of TNF in
brain ischemia is controversial. At pathophysiological
levels, TNF-a h a sb e e ns h o w nn o to n l yt ob ei n v o l v e d
in necrosis, but also in the regulation of caspases and
other apoptotic factors [32,33]. Its initiation of an
inflammatory response may result in disruption of the
blood-brain barrier, compromising the protective barrier
between the brain and the systemic circulation. Thus
the infiltration of peripheral inflammatory cells to the
affected brain region can occur, exacerbating the overall
inflammatory response [34,35]. TNF-a has also been
shown to stimulate astrocyte [36] and microglial [15]
activation and proliferation in a paracrine and/or auto-
crine fashion.
In early studies with TNF KO mice Mattson showed
clearly that damage to neurons by focal cerebral ische-
mia and excitotoxic insults was enhanced in TNFR-KO
mice, implicating TNF as a neuroprotectant in the
brain [37]. These effects were shown to involve
increased oxidative stress and supression of injury
induced microglial activation. Later studies by the same
group implicated both TNFRs, namely p55 and p75 in
these effects [38]. More recently Lambertsen et al.
(2009) have recently identified a neuroprotective role
for microglial dervied TNF in cerebral ischemia an
affect shown to be due to TNF-p55R activity [39]. In
this work with TNF-p55R KO mice they also reported
a reduced microglial population size and interestingly
reduced Toll-like receptor 2 expression. The work of
Taoufik et al (2008) investigated the molecular
mechanisms of the neuroprotective effects of TNF
using TNFR1 KO mice using the model of middle cere-
bral artery occlusion. They found that erythropoietin
(originally described as a hematopoietic growth factor)
and vascular endothelial growth factor (VEGF) induced
neuroprotection against glucose deprivation, NMDA
excitotoxicity and oxygen glucose deprivation and that
these effects required the presence of TNFR1 [40].
These data together provide stong evidence for that
TNF plays a key role in determining the survival of
endangered neurons in cerebral ischemia.
Glial cells contain metabotropic type 2 glutamate
receptors (mGluR2) on their plasma membrane, which,
once activated by excessive glutamate release during cer-
ebral ischemia, results in stimulation of IP3-mediated
Ca
2+ release from intracellular stores and the release of
‘gliotransmitters’ such as TNF-a, ATP and glutamate
itself [41]. TNF-a can act in both an autocrine and a
paracrine fashion, stimulating its receptors found on
glial and neighbouring neuronal cell membranes. Stimu-
lation of TNFR’s present on microglial membranes sti-
mulates the upregulation of glutaminase, an enzyme
involved in the conversion of glutamine to its active
form, glutamate. Excess glutamate production in the
microglia may result in the uncontrolled release of glu-
tamate into the extracellular space via hemichannels
present on the microglial membrane [42]. TNF-a can
also have negative effects on glutamate uptake and
degradation by astrocytes. Activation of the TNFR1-cas-
pase 3 pathway results in the cleavage of EAAT2 at the
intracellular C-terminal domain of the glutamate trans-
porter, rendering it inactive [43]. Stimulation of the
NFkB pathway in astrocytes by TNF-a, decreases the
transcription and expression of EAAT2 on the glial
membrane, reducing glutamate uptake from the synaptic
cleft [44]. Although this response may favour glial survi-
val by preventing overaccumulation of glutamate in the
astrocytes, neuronal surviv a lw i l lb ef u r t h e rc o m p r o -
mised as a result, due to prolonged excitation of these
cells by excessive glutamate in the synaptic cleft [45].
TNF-a stimulation of astrocytes may also result in PKC
mediated activation of NFkB transcription, and upregu-
lation of interleukin-6, a potent inflammatory mediator,
thus exacerbating the inflammatory response [46].
Activation of the TNFR1 receptor on neurons initiates
the caspase cascade involved in apoptosis [8] Badiola et
al. (2009) using TNFR KO mice and an OGD model in
cortical cultures showed that TNF induced apopotic cell
death involves TNFR1-activation of caspase-8 and cas-
pase-3 but not caspase-9 [33]. Neuronal TNFR1-
mediated IP3 activation may induce the insertion of Ca
2+
permeable AMPARs into the post-synaptic density, thus
may contribute to Ca
2+-mediated cell death in this way,
during an ischemic insult [47]. Indeed Stellwagen and his
colleagues also found that treatment of hippocampal cul-
tures with TNF-a (1 μg/ml) for 15 min was sufficient to
i n d u c ear e d u c t i o ni ns u r f a c eG A B A A receptors in the
same cohort of cells (most likely due to endocytosis),
reducing the responsiveness of these cells to inhibitory
input, which would further exacerbate excitotoxicity dur-
ing an ischemic insult [47].
Together, these studies highlight the vast detrimental
effects of TNF-a on both glial and neuronal functioning
during cerebral ischemia. TNF-a mediated cell destruc-
tion may be mediated directly, via activation of its
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indirectly by enhancing glutamate excitotoxicity. Overall
there is convincing data supporting both detrimental
and protective effects of TNF in brain ischemia. Figure 2
summarises some of these processes.
TNF-a and ischemic preconditioning
A milder form of a cerebral ischemic event, known as a
transient ischemic attack (TIA), results in a brief disrup-
tion of the cerebral blood supply and temporary presen-
tation of stroke-like symptoms. A TIA may occur upon
narrowing or temporary blockage of a cerebral artery by
a thrombus or an embolism. A TIA is considered a
warning sign that a more severe stroke may occur if
appropriate measures are not taken to prevent it. Recent
studies have shown that a mild TIA within a narrow
time window prior to a stroke may enhance the toler-
ance of the brain to deal with this second insult. In
2000, a study of 2490 stroke patients, found that a TIA
must be at least 5 min in duration in order to induce
neuroprotection [48]. Conversely, a prolonged TIA
(greater than one week) or repetitious TIA’s cancel out
this neuroprotective effect. This study also found that
the neuroprotective effect of a TIA is transient, greatly
diminishing within 72 h. Interestingly, a clinical study
carried out by Castillo et al. (2003) found that plasma
levels of TNF-a remained elevated in patients for up to
72 h after a TIA, and that those who experienced a TIA
prior to a stroke within this time window had a better
functional outcome than those who did not [49]. Corre-
sponding with the in vivo findings, a study carried out
in mixed cortical cultures in vitro found, using brief
oxygen and glucose deprivation (OGD) as a model of
TIA, that the OGD-induced neuroprotection was also
lost within 72 h [50]. The preconditioning effect of a
TIA can also been demonstrated in many experimental
models of stroke, both in vivo [51-53] and in vitro
[54,55].
Elevation of both glutamate and TNF-a may persist
for days after a TIA and contribute to the enhancement
of cellular defences against a more severe ischemic
insult [56-59]. To date, extensive research has been car-
ried out in order to isolate the proposed mechanisms of
ischemic tolerance caused by glutamate or TNF-a eleva-
tion as part of a TIA. Incubation of primary neuronal
cells with TNF-a (100 ng/ml) for 48 h, prior to excito-
toxic AMPA or NMDA exposure, significantly reduced
the peak Ca
2+ response induced by these ionotrophic
glutamate receptor agonists [60]. As calcium is a well
known mediator of cell death, these findings suggest
that TNF-a mediated neuroprotection may be as a
result of decreasing conductance of these ionotrophic
receptors to Ca
2+, or reducing their sensitivity to these
glutamatergic agents. This study also found that TNF-a
induced upregulation of NFkB gene transcription of
neuroprotective mediators such as calbindin, a calcium
chelator, and manganese superoxide dismutase
(MnSOD), a powerful anti-oxidant which contribute to
this neuroprotective response [60]. However, it must be
noted that these experiments were carried out in pri-
mary neuronal cultures, in the absence of the glial cell
population.
A study carried out by Bernardino et al. (2005) used
organotypic hippocampal cultures to investigate TNF-a
mediated preconditioning against subsequent AMPA
exposure [61]. Organotypic hippocampal cultures best
represent the synaptic morphology of the hippocampus
in vivo, as the circuitry of the hippocampus is main-
tained and the contribution of the glial cell population
to the overall response can taken into account [62].
Incubation of organotypic hippocampal cultures with 1
ng/ml TNF-a for 24 h increased the resistance of the
CA 1 pyramidal cells to a subsequent AMPA insult,
while co-exposure of TNF-a and AMPA also had a neu-
roprotective effect compared to cultures exposed to
AMPA alone [61]. However, this neuroprotective effect
was lost when the concentration of TNF-a was
increased to 10 ng/ml, while co-exposure exacerbated
AMPA-induced toxicity, revealing a concentration-
dependent element to the TNF-a mediated response.
We have also shown in our laboratories using organoty-
pic hippocampal slices that attenuation in resting Ca
2+
activity and Ca
2+ related responsiveness of cells within
the hippocampus as a result of glutamate or TNF-a
pre-exposure, may contribute to the development of
ischemic tolerance [63]. We found that inhibition of the
p38 MAP kinase pathway with SB 203580 (10 μM),
before and during TNF-a exposure resulted in a com-
plete reversal of TNF-a’s effect on glutamate-induced
Ca
2+ influx, 24 h post treatment.
In an in vivo study carried out by Sotgiu and collea-
gues, they showed using a multiple linear regression
analysis that there was a positive linear correlation
between blood levels of TNF-a (measured 6-20 h post-
stroke) and the clinical severity of the cerebral ischemic
event, supporting these in vitro findings [64]. As a TIA
is a much milder form of stroke, it is possible that the
lower levels of TNF-a produced during a TIA contri-
bute to induction of neuroprotective mechanisms, while
more pathophysiological levels of TNF-a reached during
stroke, exacerbate glutamate-mediated excitotoxicity and
cell death. Coinciding with this hypothesis, it is possible
that the mild elevation of cell death signalling molecules
during ischemic preconditioning, such as ceramide and
ROS, may trigger the upregulation of neuroprotective
mediators, preparing cellular defences against a subse-
quent more severe ischemic insult [55,65]. Stimulation
of neuronal TNFR1 receptors during an initial ischemic
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Page 4 of 8Figure 2 Summary of the detrimental effects of TNF-a on both neuronal and glial cells during cerebral ischemia. TNF-a synthesis and
release for both neuronal and glial cells may be induced via stimulation of mGlu2R by glutamate. TNF-a may then act in an autocrine and/or
paracrine fashion, modulating neuronal and glial signalling. Direct stimulation of the TNFR1-caspase 3 pathway results in inactivation of glial
EAAT2s, while activation of the NFkB pathway reduces the synthesis and expression of this glutamate transporter. Upregulation of glutaminase in
response to microglial TNFR activation also enhances glutamate synthesis and release, elevating levels of this neurotransmitter in the synapse.
TNFR1 signalling may also enhance AMPAR trafficking into the postsynaptic membrane, enhancing the sensitivity of the cells to glutamate.
Together, these effects result in the exacerbation of glutamate excitotoxicity during cerebral ischemia.
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increased gene transcription and protein expression of
EAAT3 on the neuronal membrane, thus priming the
neurons to mop up excess glutamate more rapidly and
efficiently from the synaptic cleft, reducing the extent of
g l u t a m a t ee x c i t o t o x i c i t yw h i c hm a yb ei n d u c e db ya
more severe ischemic insult [66].
The contribution of mild acute glutamate elevation
during a TIA to the development of ischemic tolerance
has also been extensively studied in vitro. During an
ischemic event, oxygen and glucose depletion induces
neuronal dysfunction and uncontrolled excessive gluta-
mate release. Oxygen and glucose deprivation (OGD)
can be induced in vitro by incubating the cultures in
an anaerobic chamber with a gas composition of up to
95% N2 and 5% CO2, while replacing the culture
media with one which is glucose-free. These conditions
were found to mimic those occurring in vivo, by indu-
cing both Ca
2+-dependent and Ca
2+-independent cell
death pathways in both neuron a la n dg l i a lc e l lp o p u l a -
tions [67]. In some cases 2-deoxy-glucose may be
added to the glucose free media to inhibit the glycoly-
sis, thus preventing the production of endogenous
glucose. In accordance with data obtained from in vivo
studies, a short exposure of cultured cells to OGD (10-
30 min) mimics the events of a TIA, inducing neuro-
protection against a subsequent more severe insult
[50]. As OGD induces endogenous glutamate elevation,
the increased activity of this excitatory neurotransmit-
ter at its receptors was hypothesised as one of the con-
tributing factors to the development of ischemic
tolerance. Indeed, Grabb and Choi (1999) discovered
that exposure of the cultures with brief exposure to a
mild concentration of glutamate (10-30 μM, 30 min)
induced a similar level of neuroprotection against a
more prolonged OGD insult applied 24 h later. This
effect was also replicated using sublethal NMDA expo-
sure (5-10 μM, 30 min) as a preconditioning agent,
while inhibition of NMDAR’s during OGD abolished
the neuroprotective response, suggesting that gluta-
mate-mediated neuroprotection as a result of NMDAR
activation [50]. Activation of NMDAR’sd u r i n gg l u t a -
mate preconditioning has been shown to induce Ca
2
+-mediated activation of various signalling pathways
involved in upregulation neuroprotective mediators
[58,68]. Pharmacological dissection of the signalling
cascades known to the activated by Ca
2+,u s i n gav a r i -
ety of antagonists revealed that Ca
2+-mediated activa-
tion CaMK-II which in turn phosphorylates CREB,
inducing CRE-mediated gene transcription of Bcl-2, a
protein known to suppress apoptosis. This effect was
further validated in vivo using temporary middle cere-
bral artery occlusion (mCAO) to induce TIA-like
elevation in glutamate transmission [68]. Ischemic tol-
erance induced by OGD may also involve activation of
other glutamate receptor types such as the ionotrophic
AMPAR and the metabotrophic receptor mGluR1, as
antagonism of these receptors was found to attenuate
OGD-mediated preconditioning to a subsequent severe
OGD insult, in organotypic hippocampal cultures [69].
It is important to note that TNF-a and glutamate
share numerous downstream signalling pathways such
as CREB, NFkB and MAPK, thus their contribution to
the development of ischemic tolerance during a TIA
may overlap [59,68,70-73]. Indeed, glutamate itself can
stimulate the release of pro-inflammatory cytokines such
as TNF-a. Keeping this in mind, it is possible that appli-
cation of exogenous glutamate may have a knock-on
TNF-a mediated effect, adding a layer of complexity to
the interpretation of experimental findings [74].
Conclusions
Like many neurological disorders an imbalance in neu-
rotransmission and inflammatory responses within the
brain may negatively affect neuronal function, and in
more severe cases may result in cell death. Excessive
glutamate signalling during cerebral ischemia has been
implicated in the development of excitotoxicity, while
hightened TNF-a signalling mediates an inflammatory
response which is known to exacerbate this detrimental
glutamate response. However, mild elevation of gluta-
mate and TNF-a during an acute TIA has highlighted
their role as preconditioning stimuli, inducing an endo-
genous neuroprotective response against subsequent
ischemic insults. Numerous pathways and effector mole-
cules are involved in this enhanced tolerance, ultimately
resulting in a more stringent regulation of neuronal sig-
nalling and calcium responses to excessive glutamate sti-
mulation, induced under conditions of cerebral
ischemia.
List of Abbreviations
(AMPAR): 2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl) propanoic acid
receptor; (ATP): adenosine tri-phosphate; (ATPase): adenosine tri-
phosphatase; (Bcl-2): B cell lymphoma 2; (Ca
2+): calcium; (CAM-KII): calcium/
calmodulin -dependent protein kinase 2; (CREB): cAMP response element
binding protein; (EAAT): excitatory amino acid transporter; (FADD): fas-
associated death domain; (GD): glucose deprivation; (GABA): γ-aminobutyric
acid; (IkB): inhibitor of kB; (IKKβ): inhibitor of nuclear factor kappa-B kinase
subunit beta; (IP3): inositol triphosphate; (IRS): insulin receptor substrate;
(JNK): c-Jun N-terminal kinase; (KO): knock-out; (MAPK): mitogen-activated
protein kinase; (mCAO): middle cerebral artery occlusion; (mGluR):
metabotrophic glutamate receptor; (MnSOD): manganese superoxide
dismutase; (NFkB): nuclear factor kappa B; (NMDA): N-Methyl-D-aspartic acid;
(OGD): oxygen and glucose deprivation; (PI-3): phosphoinositide- 3; (RAIDD):
RIP-associated ICH-1 homologous protein with a death domain; (RIP):
receptor interacting protein; (SB203580): 4-[5-(4-Fluorophenyl)-2-[4-
(methylsulfonyl)phenyl]-1H-imidazol-4-yl]pyridine; (TIA): transient ischemic
attack; (TNF-α): tumour necrosis factor-alpha; (TNFR): tumour necrosis factor-
alpha receptor; (TRAF): TNF-α receptor-associated factor; (TRADD): TNF-α
Watters and O’Connor Journal of Neuroinflammation 2011, 8:87
http://www.jneuroinflammation.com/content/8/1/87
Page 6 of 8receptor-associated death domain; (VDCC): voltage-dependent calcium
channel.
Acknowledgements
We would like to thank Science Foundation Ireland (SFI; 09/RFP/NES2450)
and University College Dublin for financial support.
Authors’ contributions
OW participated in the design of the study, carried out the organotypic and
primary hippocampal culture studies referred to in the manuscript,
performed the statistical analysis and drafted the manuscript. JOC conceived
the study, and participated in its design and coordination and helped to
draft the manuscript. Both authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 3 June 2011 Accepted: 2 August 2011
Published: 2 August 2011
References
1. Suyama K: Changes of neuronal transmission in the hippocampus after
transient ischemia in spontaneously hypertensive rats and the
protective effects of MK-801. Stroke 1992, 23:260-266.
2. Jarvis CR, Anderson TR, Andrew RD: Anoxic depolarization mediates acute
damage independent of glutamate in neocortical brain slices. Cereb
Cortex 2001, 11:249-259.
3. Kohno K, Hoehn-Berlage M, Mies G, Back T, Hossmann KA: Relationship
between diffusion-weighted MR images, cerebral blood flow, and
energy state in experimental brain infarction. Magn Reson Imaging 1995,
13:73-80.
4. Rosenberg GA: Ischemic brain edema. Prog Cardiovasc Dis 1999,
42:209-216.
5. Barber PA, Auer RN, Buchan AM, Sutherland GR: Understanding and
managing ischemic stroke. Can J Physiol Pharmacol 2001, 79:283-296.
6. Martin RL, Lloyd HGE, Cowan AI: The early events of oxygen and glucose
deprivation: setting the scene for neuronal death? Trends in Neurosciences
1994, 17:251-257.
7. Ankarcrona M, Dypbukt JM, Bonfoco E, Zhivotovsky B, Orrenius S, Lipton SA,
Nicotera P: Glutamate-induced neuronal death: a succession of necrosis
or apoptosis depending on mitochondrial function. Neuron 1995,
15:961-973.
8. Kogo J, Takeba Y, Kumai T, Kitaoka Y, Matsumoto N, Ueno S, Kobayashi S:
Involvement of TNF-alpha in glutamate-induced apoptosis in a
differentiated neuronal cell line. Brain Res 2006, 1122:201-208.
9. Liu T, Clark RK, McDonnell PC, Young PR, White RF, Barone FC,
Feuerstein GZ: Tumor necrosis factor-alpha expression in ischemic
neurons. Stroke 1994, 25:1481-1488.
10. Bullock R, Zauner A, Woodward J, Young HF: Massive persistent release of
excitatory amino acids following human occlusive stroke. Stroke 1995,
26:2187-2189.
11. Davalos A, Castillo J, Serena J, Noya M: Duration of glutamate release after
acute ischemic stroke. Stroke 1997, 28:708-710.
12. Ventura R, Harris KM: Three-Dimensional Relationships between
Hippocampal Synapses and Astrocytes. The Journal of Neuroscience 1999,
19:6897-6906.
13. Dziewulska D, Mossakowski MJ: Cellular expression of tumor necrosis
factor a and its receptors in human ischemic stroke. Clin Neuropathol
2003, 22:35-40.
14. Figiel I, Dzwonek K: TNF[alpha] and TNF receptor 1 expression in the
mixed neuronal-glial cultures of hippocampal dentate gyrus exposed to
glutamate or trimethyltin. Brain Research 2007, 1131:17.
15. Dopp JM, Mackenzie-Graham A, Otero GC, Merrill JE: Differential
expression, cytokine modulation, and specific functions of type-1 and
type-2 tumor necrosis factor receptors in rat glia. J Neuroimmunol 1997,
75:104-112.
16. Bebo BF Jr, Linthicum DS: Expression of mRNA for 55-kDa and 75-kDa
tumor necrosis factor (TNF) receptors in mouse cerebrovascular
endothelium: effects of interleukin-1 beta, interferon-gamma and TNF-
alpha on cultured cells. J Neuroimmunol 1995, 62:161-167.
17. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA Jr, Goeddel DV:
The two different receptors for tumor necrosis factor mediate distinct
cellular responses. Proc Natl Acad Sci USA 1991, 88:9292-9296.
18. Dembic Z, Loetscher H, Gubler U, Pan YC, Lahm HW, Gentz R,
Brockhaus M, Lesslauer W: Two human TNF receptors have similar
extracellular, but distinct intracellular, domain sequences. Cytokine
1990, 2:231-237.
19. Marchetti L, Klein M, Schlett K, Pfizenmaier K, Eisel UL: Tumor necrosis
factor (TNF)-mediated neuroprotection against glutamate-induced
excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation.
Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-
kinase-dependent NF-kappa B pathway. J Biol Chem 2004,
279:32869-32881.
20. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ: A domain in
TNF receptors that mediates ligand-independent receptor assembly and
signaling. Science 2000, 288:2351-2354.
21. Pinckard JK, Sheehan KC, Schreiber RD: Ligand-induced formation of p55
and p75 tumor necrosis factor receptor heterocomplexes on intact cells.
J Biol Chem 1997, 272:10784-10789.
22. Pinckard JK, Sheehan KC, Arthur CD, Schreiber RD: Constitutive shedding
of both p55 and p75 murine TNF receptors in vivo. J Immunol 1997,
158:3869-3873.
23. Rothe M, Wong SC, Henzel WJ, Goeddel DV: A novel family of putative
signal transducers associated with the cytoplasmic domain of the 75
kDa tumor necrosis factor receptor. Cell 1994, 78:681-692.
24. Song HY, Regnier CH, Kirschning CJ, Goeddel DV, Rothe M: Tumor necrosis
factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-
kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF
receptor-associated factor 2. Proc Natl Acad Sci USA 1997, 94:9792-9796.
25. Hsu H, Xiong J, Goeddel DV: The TNF receptor 1-associated protein
TRADD signals cell death and NF-kappa B activation. Cell 1995,
81:495-504.
26. Chen G, Goeddel DV: TNF-R1 signaling: a beautiful pathway. Science 2002,
296:1634-1635.
27. Pimentel-Muiños FX, Seed B: Regulated Commitment of TNF Receptor
Signaling: A Molecular Switch for Death or Activation. Immunity 1999,
11:783-793.
28. MacEwan DJ: TNF receptor subtype signalling: differences and cellular
consequences. Cell Signal 2002, 14:477-492.
29. Liu ZG, Hsu H, Goeddel DV, Karin M: Dissection of TNF receptor 1 effector
functions: JNK activation is not linked to apoptosis while NF-kappaB
activation prevents cell death. Cell 1996, 87:565-576.
30. Reddy SA, Huang JH, Liao WS: Phosphatidylinositol 3-kinase as a
mediator of TNF-induced NF-kappa B activation. J Immunol 2000,
164:1355-1363.
31. Botchkina GI, Meistrell ME, Botchkina IL, Tracey KJ: Expression of TNF and
TNF receptors (p55 and p75) in the rat brain after focal cerebral
ischemia. Mol Med 1997, 3:765-781.
32. Schneider-Brachert W, Tchikov V, Neumeyer J, Jakob M, Winoto-Morbach S,
Held-Feindt J, Heinrich M, Merkel O, Ehrenschwender M, Adam D, et al:
Compartmentalization of TNF receptor 1 signaling: internalized TNF
receptosomes as death signaling vesicles. Immunity 2004, 21:415-428.
33. Badiola N, Malagelada C, Llecha N, Hidalgo J, Comella JX, Sabriá J,
Rodríguez-Alvarez J: Activation of caspase-8 by tumour necrosis factor
receptor 1 is necessary for caspase-3 activation and apoptosis in
oxygen-glucose deprived cultured cortical cells. Neurobiol Dis 2009,
35:438-47.
34. Hughes CC, Male DK, Lantos PL: Adhesion of lymphocytes to cerebral
microvascular cells: effects of interferon-gamma, tumour necrosis factor
and interleukin-1. Immunology 1988, 64:677-681.
35. Tsao N, Hsu HP, Wu CM, Liu CC, Lei HY: Tumour necrosis factor-alpha
causes an increase in blood-brain barrier permeability during sepsis. J
Med Microbiol 2001, 50:812-821.
36. Selmaj K, Farooq M, Norton W, Raine C, Brosnan C: Proliferation of
astrocytes in vitro in response to cytokines. A primary role for tumor
necrosis factor. The Journal of Immunology 1990, 144:129-135.
37. Bruce AJ, Boling W, Kindy MS, Peschon J, Kraemer PJ, Carpenter MK,
Holtsberg FW, Mattson MP: Altered neuronal and microglial responses to
excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat
Med 1996, 2:788-94.
Watters and O’Connor Journal of Neuroinflammation 2011, 8:87
http://www.jneuroinflammation.com/content/8/1/87
Page 7 of 838. Gary DS, Bruce-Keller AJ, Kindy MS, Mattson MP: Ischemic and excitotoxic
brain injury is enhanced in mice lacking the p55 tumor necrosis factor
receptor. J Cereb Blood Flow Metab 1998, 18:1283-7.
39. Lambertsen KL, Clausen BH, Babcock AA, Gregersen R, Fenger C,
Nielsen HH, Haugaard LS, Wirenfeldt M, Nielsen M, Dagnaes-Hansen F,
Bluethmann H, Faergeman NJ, Meldgaard M, Deierborg T, Finsen B:
Microglia protect neurons against ischemia by synthesis of tumor
necrosis factor. J Neurosci 2009, 29:1319-30.
40. Taoufik E, Petit E, Divoux D, Tseveleki V, Mengozzi M, Roberts ML, Valable S,
Ghezzi P, Quackenbush J, Brines M, Cerami A, Probert L: TNF receptor I
sensitizes neurons to erythropoietin- and VEGF-mediated
neuroprotection after ischemic and excitotoxic injury. Proc Natl Acad Sci
USA 2008, 105:6185-90.
41. Perea G, Araque A: Synaptic regulation of the astrocyte calcium signal. J
Neural Transm 2005, 112:127-135.
42. Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y,
Mizuno T, Suzumura A: Tumor necrosis factor-alpha induces neurotoxicity
via glutamate release from hemichannels of activated microglia in an
autocrine manner. J Biol Chem 2006, 281:21362-21368.
43. Boston-Howes W, Gibb SL, Williams EO, Pasinelli P, Brown RH Jr, Trotti D:
Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J
Biol Chem 2006, 281:14076-14084.
44. Sitcheran R, Gupta P, Fisher PB, Baldwin AS: Positive and negative
regulation of EAAT2 by NF-kappaB: a role for N-myc in TNFalpha-
controlled repression. Embo J 2005, 24:510-520.
45. Zou JY, Crews FT: TNF alpha potentiates glutamate neurotoxicity by
inhibiting glutamate uptake in organotypic brain slice cultures:
neuroprotection by NF kappa B inhibition. Brain Res 2005, 1034:11-24.
46. Sparacio SM, Zhang Y, Vilcek J, Benveniste EN: Cytokine regulation of
interleukin-6 gene expression in astrocytes involves activation of an NF-
kappa B-like nuclear protein. J Neuroimmunol 1992, 39:231-242.
47. Stellwagen D, Beattie EC, Seo JY, Malenka RC: Differential regulation of
AMPA receptor and GABA receptor trafficking by tumor necrosis factor-
alpha. J Neurosci 2005, 25:3219-3228.
48. Moncayo J, de Freitas GR, Bogousslavsky J, Altieri M, van Melle G: Do
transient ischemic attacks have a neuroprotective effect? Neurology 2000,
54:2089-2094.
49. Castillo J, Moro MA, Blanco M, Leira R, Serena J, Lizasoain I, Davalos A: The
release of tumor necrosis factor-alpha is associated with ischemic
tolerance in human stroke. Ann Neurol 2003, 54:811-819.
50. Grabb MC, Choi DW: Ischemic tolerance in murine cortical cell culture:
critical role for NMDA receptors. J Neurosci 1999, 19:1657-1662.
51. Barone FC, White RF, Spera PA, Ellison J, Currie RW, Wang X, Feuerstein GZ:
Ischemic preconditioning and brain tolerance: temporal histological and
functional outcomes, protein synthesis requirement, and interleukin-1
receptor antagonist and early gene expression. Stroke 1998, 29:1937-1950,
discussion 1950-1931.
52. Kitagawa K, Matsumoto M, Tagaya M, Hata R, Ueda H, Niinobe M, Handa N,
Fukunaga R, Kimura K, Mikoshiba K, et al: ’Ischemic tolerance’
phenomenon found in the brain. Brain Res 1990, 528:21-24.
53. Matsushima K, Hakim AM: Transient forebrain ischemia protects against
subsequent focal cerebral ischemia without changing cerebral perfusion.
Stroke 1995, 26:1047-1052.
54. Pringle AK, Thomas SJ, Signorelli F, Iannotti F: Ischaemic pre-conditioning
in organotypic hippocampal slice cultures is inversely correlated to the
induction of the 72 kDa heat shock protein (HSP72). Brain Res 1999,
845:152-164.
55. Liu J, Ginis I, Spatz M, Hallenbeck JM: Hypoxic preconditioning protects
cultured neurons against hypoxic stress via TNF-alpha and ceramide. Am
J Physiol Cell Physiol 2000, 278:C144-153.
56. Wang X, Li X, Erhardt JA, Barone FC, Feuerstein GZ: Detection of tumor
necrosis factor-alpha mRNA induction in ischemic brain tolerance by
means of real-time polymerase chain reaction. J Cereb Blood Flow Metab
2000, 20:15-20.
57. Saha RN, Liu X, Pahan K: Up-regulation of BDNF in astrocytes by TNF-
alpha: a case for the neuroprotective role of cytokine. J Neuroimmune
Pharmacol 2006, 1:212-222.
58. Lin CH, Chen PS, Gean PW: Glutamate preconditioning prevents neuronal
death induced by combined oxygen-glucose deprivation in cultured
cortical neurons. Eur J Pharmacol 2008, 589:85-93.
59. Saha RN, Ghosh A, Palencia CA, Fung YK, Dudek SM, Pahan K: TNF-alpha
preconditioning protects neurons via neuron-specific up-regulation of
CREB-binding protein. J Immunol 2009, 183:2068-2078.
60. Glazner GW, Mattson MP: Differential effects of BDNF, ADNF9, and
TNFalpha on levels of NMDA receptor subunits, calcium homeostasis,
and neuronal vulnerability to excitotoxicity. Exp Neurol 2000, 161:442-452.
61. Bernardino L, Xapelli S, Silva AP, Jakobsen B, Poulsen FR, Oliveira CR,
Vezzani A, Malva JO, Zimmer J: Modulator effects of interleukin-1beta and
tumor necrosis factor-alpha on AMPA-induced excitotoxicity in mouse
organotypic hippocampal slice cultures. J Neurosci 2005, 25:6734-6744.
62. De Simoni A, Griesinger CB, Edwards FA: Development of rat CA1
neurones in acute versus organotypic slices: role of experience in
synaptic morphology and activity. J Physiol 2003, 550:135-147.
63. Watters O, Pickering M, O’Connor JJ: Preconditioning effects of tumor
necrosis factor-alpha and glutamate on calcium dynamics in rat
organotypic hippocampal cultures. J Neuroimmunol 2011, 234:27-39.
64. Sotgiu S, Zanda B, Marchetti B, Fois ML, Arru G, Pes GM, Salaris FS, Arru A,
Pirisi A, Rosati G: Inflammatory biomarkers in blood of patients with
acute brain ischemia. Eur J Neurol 2006, 13:505-513.
65. Wilde GJ, Pringle AK, Sundstrom LE, Mann DA, Iannotti F: Attenuation and
augmentation of ischaemia-related neuronal death by tumour necrosis
factor-alpha in vitro. Eur J Neurosci 2000, 12:3863-3870.
66. Pradillo JM, Hurtado O, Romera C, Cardenas A, Fernandez-Tome P, Alonso-
Escolano D, Lorenzo P, Moro MA, Lizasoain I: TNFR1 mediates increased
neuronal membrane EAAT3 expression after in vivo cerebral ischemic
preconditioning. Neuroscience 2006, 138:1171-1178.
67. Goldberg MP, Choi DW: Combined oxygen and glucose deprivation in
cortical cell culture: calcium-dependent and calcium-independent
mechanisms of neuronal injury. J Neurosci 1993, 13:3510-3524.
68. Mabuchi T, Kitagawa K, Kuwabara K, Takasawa K, Ohtsuki T, Xia Z, Storm D,
Yanagihara T, Hori M, Matsumoto M: Phosphorylation of cAMP response
element-binding protein in hippocampal neurons as a protective
response after exposure to glutamate in vitro and ischemia in vivo. J
Neurosci 2001, 21:9204-9213.
69. Werner CG, Scartabelli T, Pancani T, Landucci E, Moroni F, Pellegrini-
Giampietro DE: Differential role of mGlu1 and mGlu5 receptors in rat
hippocampal slice models of ischemic tolerance. Eur J Neurosci 2007,
25:3597-3604.
70. Guerrini L, Blasi F, Denis-Donini S: Synaptic activation of NF-kappa B by
glutamate in cerebellar granule neurons in vitro. Proc Natl Acad Sci USA
1995, 92:9077-9081.
71. Tamatani M, Che YH, Matsuzaki H, Ogawa S, Okado H, Miyake S, Mizuno T,
Tohyama M: Tumor necrosis factor induces Bcl-2 and Bcl-x expression
through NFkappaB activation in primary hippocampal neurons. J Biol
Chem 1999, 274:8531-8538.
72. Irving EA, Barone FC, Reith AD, Hadingham SJ, Parsons AA: Differential
activation of MAPK/ERK and p38/SAPK in neurones and glia following
focal cerebral ischaemia in the rat. Brain Res Mol Brain Res 2000, 77:65-75.
73. Scholzke MN, Potrovita I, Subramaniam S, Prinz S, Schwaninger M:
Glutamate activates NF-kappaB through calpain in neurons. Eur J
Neurosci 2003, 18:3305-3310.
74. Chaparro-Huerta V, Rivera-Cervantes MC, Flores-Soto ME, Gomez-Pinedo U,
Beas-Zarate C: Proinflammatory cytokines and apoptosis following
glutamate-induced excitotoxicity mediated by p38 MAPK in the
hippocampus of neonatal rats. J Neuroimmunol 2005, 165:53-62.
doi:10.1186/1742-2094-8-87
Cite this article as: Watters and O’Connor: A role for tumor necrosis
factor-a in ischemia and ischemic preconditioning. Journal of
Neuroinflammation 2011 8:87.
Watters and O’Connor Journal of Neuroinflammation 2011, 8:87
http://www.jneuroinflammation.com/content/8/1/87
Page 8 of 8